• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
MRNS

MRNS

Marinus Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD0.55

+0.00 (+0.00%)

Company Profile

CEO

Scott N. Braunstein

IPO Date

2014-07-31

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$0.55

Prev. Close

$0.55

Day Low

$0.55

Day High

$0.55

52W Low

$0.22

52W High

$10.50

Market Cap

$0.03B

Volume

1.10M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

14.7%

Avg Negative

14.2%

Avg Neutral

71.2%

News Feed

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

Business Wire·6/11/2021·↑ positive

New Strong Sell Stocks for June 4th

Zacks Investment Research·6/4/2021·↑ positive

Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/17/2021·↓ negative

Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research·5/17/2021·↑ positive

Marinus Pharmaceuticals: Q1 Earnings Insights

Benzinga·5/17/2021·↓ negative

Marinus Pharmaceuticals Reschedules First Quarter 2021 Financial Results Conference Call

Business Wire·5/13/2021·↓ negative

Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire·4/12/2021·↑ positive

Marinus Pharmaceuticals Appoints Dr. Saraswathy (Sara) Nochur to Board of Directors

Business Wire·3/24/2021·↑ positive

Marinus Pharmaceuticals to Provide Business Update and Announce Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021

Business Wire·2/10/2021·↓ negative

Marinus (MRNS) Gets Positive FDA Response for Ganaxolone Study

Zacks Investment Research·1/14/2021·↑ positive